Archives: Speakers

CEO Dr Michael-Robin Witt holds a Ph.D. in Neuropharmacology from the Royal School of Pharmacy, Copenhagen, Denmark. He has published more than 50 publications in peer-reviewed scientific journals. Following 12 years in academic research, at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark. MRW has held senior line and project management positions in Scandinavian Biotech companies including Neurosearch AB (1999-2000), AstraZeneca R&D (2000-2003), KaroBio AB (2003-2007). In 2007, MRW co-founded Axcentua Pharmaceuticals AB, acting as CSO for 5 years before joining Lead Discovery Malaysia in 2012 where he currently holds the positions of CEO & CSO. MRW joined Gabather AB in September 2014 and was appointed Principal Scientist in October 2015. He is currently CEO.

Dr Christine Natasha Ryan holds a PhD in Neuroscience from the University of Cambridge, Cambridge, UK and an MBA from Stockholm School of Economics. Following a post-doc at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark, CNR remained in Scandinavia moving to Sweden to work at Astra, which then became AstraZeneca, holding line management and competitive intelligence roles. CNR has engaged in preclinical research at blue chip companies such as AstraZeneca, smaller pharmaceutical companies, CROs and biotechs, working at Karo Bio AB, and Cerca Insights among others. CNR joined Gabather AB as Principal Scientist in 2017, becoming VP Operations in 2018.

Martine Zimmermann is Senior Vice President and Head of Regulatory Affairs, R&D & Commercial Quality at Alexion, AstraZeneca Rare Disease. Dr Zimmermann has over 25 years of combined R&D and global regulatory strategy experience. She joined Alexion in 2009 and has since then been dedicated to the registration of several orphan medicinal products across the globe, as well as to the shaping of the regulatory environment for medicines under development for rare diseases. Prior to Alexion, Dr Zimmermann held numerous R&D and regulatory roles in companies such as Aventis (now Sanofi), Servier and H. Lundbeck A/S. Dr Zimmermann also serves currently as a Director in the Board Inventiva Pharma. From 2019 to 2021 she served as a Director in the Board for CAELUM Bioscience. She received her PharmD from the University Louis Pasteur in Strasbourg, France, and is based in Zurich, Switzerland. Martine has been a champion of diversity, equality, inclusion and belonging, having been recognized by the Healthcare Businesswoman’s Association as a Luminary in 2020, and efforts by serving as an executive sponsor for Alexion’s flagship Women In Leadership (WIL) employee resource group.

Passionate of data and addicted to results, my goal is to help customers to reach outstanding benefits from digital transformation embracing new technologies thanks to a business education background of more than 20 years of experience in Data Driven and Artificial Intelligence companies in sales and marketing area.

Stefan Schetter is a proven expert in the field of finance. The graduate engineer has been working in the financial sector for almost 20 years. After working for SHS Viveon and Experian, he joined CRIF GmbH as Sales Director Special Accounts and Automotive. In his position at CRIF, Stefan Schetter is mainly responsible for the areas of risk management, system and process solutions for the financial sector and KYC.